Emerging Treatment Options in the Management of Resistance to Tyrosine Kinase Inhibitors in Non–Small Cell Lung Cancer
Targeted therapies and immune checkpoint inhibitors have transformed the treatment landscape for non–small cell lung cancer (NSCLC).
Tyrosine kinase inhibitors (TKIs) have contributed to an overall decline in lung cancer–related mortality, and as they move into the early-stage setting, more dramatic improvements in outcomes are expected. However, combatting TKI resistance in NSCLC is largely an unmet challenge.
Tissue next-generation sequencing and plasma circulating tumor DNA–based assays have emerged as concurrent methods to identify targetable mechanisms of resistance to TKIs at the time of clinical progression, while antibody-drug conjugates represent a promising therapeutic class for the treatment of TKI-resistant NSCLC.
- December 05, 2022
In a new study, Yale Cancer Center researchers found molecular explanations for why some lung tumors respond better to certain drugs than others. The research should help improve drug selection for lung cancer patients with different mutations in the EGF receptor, using a precision medicine approach to treatment.
- December 01, 2022
Dr. Stockhammer received the Distinguished Young Investigator Research Award at this year’s EGFR Resisters Research Summit in Chicago, IL.
- June 02, 2022
Irina Krykbaeva, a recent PhD graduate in the Department of Pathology at Yale School of Medicine, is the winner of the 2022 Milton C. Winternitz Prize in Pathology. The prize is awarded annually to the student who, in the opinion of the department faculty and staff, has done outstanding work in the course.
- April 12, 2022
Yale Pathology Meets in Madison for Department Retreat; First In-Person Gathering Since Pandemic Began
Faculty and staff of Yale Pathology went to the Water’s Edge Resort in Madison on April 2 for a full-day retreat, the department’s first in-person gathering since the coronavirus pandemic began more than two years ago.
- April 05, 2022
The American Association for Cancer Research recently announced awards to support three young scientists from Yale Cancer Center to attend the 2022 Annual Meeting of the American Association for Cancer Research (AACR) in New Orleans from April 8 to 13.
- April 10, 2021
Yale Cancer Center Study Provides New Insights into Resistance to Immune Checkpoint Inhibitors in Lung Cancer
New research by Yale Cancer Center shows insights into modeling resistance to immune checkpoint inhibitors, a form of cancer immunotherapy.
- February 25, 2021
When lung cancer and breast cancer relapse, they often metastasize in the brain. The tumors that arise in the brain develop novel characteristics, differences that oft en confer resistance to existing drug therapies and create opportunities for new detection and treatment approaches for Yale Cancer Center researchers.
- March 30, 2020
A conversation with Yale Cancer Center/Smilow Cancer Hospital scientist Katerina Politi working remotely during COVID-19
A conversation with Yale Cancer Center/Smilow Cancer Hospital scientist Katerina Politi working remotely during COVID-19.
- October 01, 2019
An all-day symposium will present the latest advances in Immuno-oncology.